- Home
- NIKI vs BOLT Comparison
NIKI vs BOLT Comparison
Compare NIKI & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIKI | BOLT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 7.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NIKI | BOLT |
|---|---|---|
| Price | $5.96 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 237.6K | 23.4K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $5.91 | $3.13 |
| 52 Week High | $10.39 | $7.20 |
Technical Indicators
Market Signals| Indicator | NIKI | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 46.59 |
| Support Level | N/A | $3.14 |
| Resistance Level | $9.43 | $4.33 |
| Average True Range (ATR) | 0.77 | 0.29 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 9.02 | 46.45 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.